NCT03366116: 5-aza-4′-Thio-2′-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 120 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known, untreated, symptomatic CNS metastases (including leptomeningeal disease) that require treatment – see trial for details

Comments are closed.

Up ↑